首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1623496

2024 年至 2031 年腫瘤消融市場（按技術、應用和地區劃分）

Tumor Ablation Market By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation), By Application (Liver Cancer, Lung Cancer, Kidney Cancer), & Region For 2024-2031

出版日期: 2024年11月21日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年至 2031 年腫瘤消融市場評估

全球癌症發生率的不斷上升以及微創治療技術的進步推動了腫瘤消融的需求。腫瘤消融採用射頻消融和微波消融等技術，為傳統手術提供了替代方法，特別是對於無法接受手術介入的患者。預計這將推動腫瘤消融市場在 2023 年的收入超過 12 億美元，並在 2031 年達到約 26 億美元的估值。

腫瘤消融術已被證實具有精準瞄準和摧毀腫瘤細胞而不傷害周圍組織的功效，目前已用於治療肝臟、肺臟和腎臟等器官中的小腫瘤，頗受青睞。由於對微創手術和技術進步的需求不斷增加，預計 2024 年至 2031 年期間市場複合年增長率將達到 12.9%。

腫瘤消融市場定義/概述

腫瘤消融是指一種微創手術，用於破壞癌細胞，而無需透過傳統手術切除腫瘤。該技術使用各種形式的能量，包括射頻、微波和冷凍消融，來破壞癌細胞。這些技術越來越多地被用於治療多種類型的癌症，特別是對於那些因年齡、健康狀況或腫瘤位置而不適合手術的患者。

腫瘤消融具有恢復時間更短、併發症更少、並且可以作為門診手術進行的優點。它常用於治療肝腫瘤、肺腫瘤、腎腫瘤和骨腫瘤。隨著對個人化、微創治療方案的需求不斷增加，腫瘤消融市場的未來在於影像導引程序的進一步發展以及與免疫療法和化學療法等其他治療方式的結合。

癌症發生率的增加會推動腫瘤消融市場的發展嗎？

全球癌症發生率不斷上升，尤其是肝癌、肺癌和腎癌，是腫瘤消融市場的主要驅動力。根據世界衛生組織 (WHO) 的數據，到 2040 年癌症患者數量預計將增加 47%，從而促使對治療方案的需求增加。腫瘤消融因其微創性以及可以治療不適合手術的患者而被廣泛接受。

此外，人們越來越傾向於透過門診手術減少住院時間和恢復時間，這進一步推動了腫瘤消融技術的採用。此外，由於醫療保健基礎設施的改善和癌症意識的不斷增強，新興市場擴大採用消融技術，預計也將推動市場成長。

高昂的治療費用和有限的先進技術取得管道是否會阻礙腫瘤消融市場的發展？

儘管腫瘤消融市場有許多好處，但它也面臨著許多課題，包括治療成本上升以及新興地區獲得先進技術的機會有限。腫瘤消融需要專門的設備和訓練有素的專業人員，這使得治療費用更高，在低收入地區更難獲得治療。這限制了醫療保健系統不發達地區腫瘤消融的普及。

此外，一些國家存在報銷問題，為醫療保健提供者和患者帶來重大課題。消融設備的高成本，加上保險覆蓋的不一致，可能會阻止小型醫院和診所提供這些治療，從而減緩市場成長。

The growing prevalence of cancer worldwide, along with technological advancements in minimally invasive treatments, is driving the demand for tumor ablation procedures. Tumor ablation, which uses techniques like radiofrequency and microwave ablation, offers an alternative to traditional surgery, especially for patients unable to undergo surgical interventions. This has enabled the Tumor Ablation Market to exceed a revenue of USD 1.2 Billion in 2023 and is projected to reach a valuation of aroundUSD 2.6 Billion by 2031.

Tumor ablation is recognized for its precision in targeting and destroying tumor cells without harming surrounding tissues, making it a preferred choice for treating small tumors in organs like the liver, lungs, and kidneys. The market is expected to grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031 due to the increasing demand for minimally invasive procedures and technological advancements.

Tumor Ablation Market: Definition/ Overview

Tumor ablation refers to minimally invasive procedures used to destroy cancer cells without removing the tumor through traditional surgery. This technology uses different forms of energy, including radiofrequency, microwave, and cryoablation, to destroy cancer cells. These techniques are increasingly being used to treat various types of cancer, particularly in patients who are poor candidates for surgery due to age, health condition, or the tumor's location.

Tumor ablation offers several benefits including reduced recovery times, fewer complications, and the ability to perform the procedure on an outpatient basis. It is commonly used in treating liver, lung, kidney, and bone tumors. As demand for personalized, minimally invasive treatment options rises, the future of the Tumor Ablation Market lies in further advancements in image-guided procedures and integration with other treatment modalities like immunotherapy and chemotherapy.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Increasing Incidence of Cancer Drive the Tumor Ablation Market?

The rising global incidence of cancer, particularly liver, lung, and kidney cancers is a significant driver of the Tumor Ablation Market. According to the World Health Organization (WHO), cancer cases are expected to rise by 47% by 2040 leading to an increased demand for treatment options. Tumor ablation due to its minimally invasive nature and ability to treat patients who are not suitable for surgery is gaining widespread acceptance.

Moreover, the growing preference for outpatient procedures which reduce hospital stays and recovery times is further boosting the adoption of tumor ablation techniques. The increased adoption of ablation technologies in emerging markets driven by improved healthcare infrastructure and rising cancer awareness is also anticipated to fuel market growth.

Will High Treatment Costs and Limited Access to Advanced Technologies Hamper the Tumor Ablation Market?

Despite its benefits, the Tumor Ablation Market faces challenges including high treatment costs and limited access to advanced technologies in developing regions. Tumor ablation procedures require specialized equipment and trained professionals which can make these treatments costly and less accessible in low-income areas. This limits the adoption of tumor ablation in regions with less-developed healthcare systems.

Furthermore, reimbursement issues in several countries pose a significant challenge for healthcare providers and patients. The high cost of ablation equipment, combined with inconsistent insurance coverage, may deter smaller hospitals and clinics from offering these treatments, potentially slowing market growth.

Category-Wise Acumens

Will Radiofrequency Ablation Continue to Dominate the Tumor Ablation Market?

Radiofrequency ablation (RFA) remains the most widely used technology in tumor ablation due to its proven efficacy and safety. RFA works by generating heat to destroy cancer cells, and it is particularly effective in treating liver and lung tumors. As it offers precise control over the ablation area minimizing damage to surrounding tissues, it continues to be a preferred method in oncology. Meanwhile, microwave ablation is rapidly gaining popularity due to its ability to create larger ablation zones making it suitable for larger tumors. Cryoablation which involves freezing the tumor cells is also gaining traction, particularly in treating kidney and prostate cancers.

While RFA is expected to remain the primary treatment, new technologies like as microwave ablation (MWA) and cryoablation are gaining interest and may challenge its dominance. MWA has benefits such as quicker treatment periods and the potential to treat larger tumors which may be appealing to both physicians and patients. Similarly, cryoablation is being investigated for its unique capacity to freeze tumors which could offer an alternative for certain patient profiles. As these technologies progress and clinical evidence for their efficacy grows, they may acquire a sizable share of the tumor ablation industry.

Will the Increasing Adoption of Tumor Ablation in Liver Cancer Treatment Drive the Market?

Liver cancer is one of the most common cancers treated with tumor ablation, and this trend is expected to continue driving market growth. The rising incidence of liver cancer, particularly in Asia-Pacific and North America is boosting the demand for ablation therapies. Tumor ablation is especially beneficial for patients with early-stage liver cancer who are not eligible for surgery. Furthermore, Lung cancer is another significant application area for tumor ablation, particularly for patients with inoperable or recurrent tumors. As healthcare providers increasingly adopt minimally invasive procedures to reduce recovery times and complications, the use of tumor ablation in lung and kidney cancer treatment is expected to rise during the forecast period.

Furthermore, advances in technology are improving the efficacy and precision of tumor ablation techniques. The development of image-guided procedures such as ultrasound and computed tomography (CT) guidance enables more precise tumor targeting, increasing treatment outcomes. As hospitals and clinics engage in updating their facilities with these new technologies, tumor ablation will become more accessible accelerating market growth. Regulatory approvals and clinical research demonstrating the safety and efficacy of these procedures boost confidence among healthcare practitioners and patients, resulting in higher adoption rates.

Country/Region-wise Acumens

Will Advancements in Healthcare Infrastructure Drive the North American Market?

The North American Tumor Ablation Market is projected to remain the largest regional market due to the region's advanced healthcare infrastructure and increasing adoption of innovative technologies. The U.S. leads the market driven by high healthcare spending, a large patient population, and the presence of key industry players. The increasing prevalence of liver, lung, and kidney cancers coupled with rising awareness about minimally invasive treatments is further propelling market growth.

Furthermore, favorable reimbursement policies and ongoing research in tumor ablation technologies are supporting the market in North America. The growing use of image-guided ablation techniques, such as MRI and CT scans to improve precision in tumor targeting is expected to drive further adoption of tumor ablation therapies.

Will Rising Cancer Incidence Fuel the Market in Asia Pacific?

The Asia Pacific region is expected to witness the highest growth in the Tumor Ablation Market due to the rising incidence of cancer and increasing healthcare investments. Countries such as China, Japan, and India are seeing a surge in cancer cases, particularly liver and lung cancer, which is fueling the demand for tumor ablation procedures. Moreover, government initiatives to improve healthcare access and the growing availability of advanced medical technologies are boosting market growth.

The growing adoption of ablation procedures in the Asia Pacific region is also driven by the growing demand for minimally invasive treatments and the rising awareness of their benefits among patients and healthcare providers. As healthcare infrastructure in emerging economies continues to improve, the Tumor Ablation Market is expected to expand significantly in this region.

Competitive Landscape

The Tumor Ablation Market is characterized by a mix of established and emerging players, each focusing on technological advancements, strategic partnerships, and product innovations to maintain a competitive edge. Companies are investing in developing new ablation technologies that offer improved precision, safety, and patient outcomes.

Some of the prominent players in the Tumor Ablation Market include:

Boston Scientific Corporation, Medtronic PLC, AngioDynamics, Inc., Merit Medical Systems, Johnson & Johnson (Ethicon), EDAP TMS S.A., IceCure Medical Ltd., RF Medical Co. Ltd., Neuwave Medical, Inc. (Johnson & Johnson).

Latest Developments

In June 2023, Boston Scientific launched a next-generation microwave ablation system designed to target larger tumors while minimizing damage to healthy tissues.

In October 2022, Medtronic announced its acquisition of an advanced cryoablation technology company to expand its portfolio in tumor ablation treatments.

1 INTRODUCTION OF GLOBAL TUMOR ABLATION MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL TUMOR ABLATION MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY

5.1 Overview
5.2 Radiofrequency Ablation (RFA)
5.3 Microwave Ablation (MWA)
5.4 Cryoablation
5.5 Other Technologies

6 GLOBAL TUMOR ABLATION MARKET, BY APPLICATION

6.1 Overview
6.2 Liver Cancer
6.3 Lung Cancer
6.4 Kidney Cancer
6.5 Others

7 GLOBAL TUMOR ABLATION MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East & Africa

8 GLOBAL TUMOR ABLATION MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Healthtronics, Inc.
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Medtronic, PLC.
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Sonacare Medical, LLC
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Boston Scientific Corporation
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Edap Tms S.A.
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Misonix, Inc.
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Galil Medical, Inc.
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Neuwave Medical, Inc.
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Mermaid Medical A/S
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 Angiodynamics, Inc.
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments